Lonza to expand bioscience testing offering with the acquisition of Redberry
Acquisition to include Red One™ solid-phase cytometry platform for rapid sterility and bioburden testing, which expands Lonza’s portfolio of automated, scalable solutions for pharmaceutical quality control
4 Nov 2025Industry news
Redberry’s Red One™ Platform for instantaneous microbial detection
Lonza has announced that it has signed an agreement to acquire Redberry SAS, an innovative company specializing in rapid microbiology testing solutions using solid-phase cytometry (SPC) technology.
The acquisition will strengthen Lonza’s testing capabilities with the addition of Redberry’s innovative Red One™ Platform, delivering exceptional speed and sensitivity in microbial detection, as well as automation to pharmaceutical QC labs. It will also further enhance Lonza’s capabilities for CDMO customers that require rapid and scalable QC solutions for short shelf-life products, reducing time-to-patient.
Redberry is a leader in SPC, providing rapid and highly precise microbial detection solutions for the pharmaceutical industry. Its state-of-the-art technology accelerates microbiology testing, delivering faster and more reliable results to ensure quality control and regulatory compliance.
The innovative Red One™ System is designed for both rapid sterility and bioburden testing, to meet growing industry requirements for speed, sensitivity and ease of use.
In April 2025, Redberry announced the successful validation of its Red One™ rapid sterility testing method that delivers results in just four days. This breakthrough solution offers a robust, GMP-compliant alternative to traditional sterility testing, which typically requires a minimum incubation time of 14 days. This improved speed will help to meet the pharmaceutical industry's growing demand for faster product release without compromising safety or regulatory standards.